Markets:

Overview

News

Currencies

International

Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

11.96 +0.24 (+2.09%)

Streaming Delayed Price Updated: 2:17 PM EDT, Sep 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Dr. Reddy's Laboratories-ADR (NYSE:RDY) Meets Key Peter Lynch Investment Criteria ↗

October 14, 2025

Discover Dr. Reddy's (RDY), a Peter Lynch-style GARP stock with strong earnings growth, low debt, and an attractive PEG ratio for long-term value.

Via Chartmill

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗

October 09, 2025

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.

Via Benzinga

Topics Government World Trade

Dr. Reddy's Laboratories-ADR (NYSE:RDY) Fits the Peter Lynch GARP Strategy ↗

September 23, 2025

Dr. Reddy's Laboratories (RDY) exemplifies Peter Lynch's GARP strategy with strong 23.6% EPS growth, a low 0.80 PEG ratio, and excellent financial health.

Via Chartmill

Dr. Reddy's Laboratories (NYSE:RDY): A Peter Lynch-Style GARP Investment ↗

September 02, 2025

Discover how Dr. Reddy's Laboratories (RDY) exemplifies Peter Lynch's GARP investing strategy with strong earnings growth, a low PEG ratio, and a robust financial profile.

Via Chartmill

DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Fits Peter Lynch's Growth at a Reasonable Price (GARP) Strategy ↗

August 12, 2025

Dr. Reddy's Labs (RDY) fits Peter Lynch's GARP strategy with steady earnings growth, strong profitability, low debt, and fair valuation—ideal for long-term investors.

Via Chartmill

Dr. Reddy’s Reports Record Revenues in Q1, Signals Steady Execution Through Transition Year

August 04, 2025

Via AB Newswire

Topics Earnings

Dr. Reddy’s Q1FY26 Financial Results

July 23, 2025

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) – A GARP Candidate Worth Watching ↗

July 22, 2025

DR. REDDY'S LABORATORIES (NYSE:RDY) fits the GARP model with strong earnings growth, solid profitability, and a reasonable valuation, making it a candidate for long-term investors.

Via Chartmill

Expanding the Preventive Care Frontier: Dr. Reddy’s Launches Sanofi’s Beyfortus® in India

July 17, 2025

Via AB Newswire

Topics Death

DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate in Pharmaceuticals ↗

June 30, 2025

DR. REDDY'S LABORATORIES (NYSE:RDY) offers strong historical growth, reasonable valuation, and solid financial health, making it a candidate for GARP investors.

Via Chartmill

DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate Worth Considering ↗

June 09, 2025

DR. REDDY'S LABORATORIES (NYSE:RDY) fits the GARP mold with strong historical growth, a low PEG ratio, and robust financials, making it a candidate for long-term investors.

Via Chartmill

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug ↗

June 05, 2025

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Via Benzinga

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

June 05, 2025

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

June 05, 2025

From Alvotech

Via GlobeNewswire

DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate Worth Considering ↗

May 16, 2025

DR. REDDY'S LABORATORIES (NYSE:RDY) offers strong earnings growth, low debt, and solid profitability, making it a candidate for GARP investors. Read why it fits the Peter Lynch strategy.

Via Chartmill

Dr. Reddy’s Q4 & Full Year FY25 Financial Results

May 09, 2025

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

How does DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) stack up against Peter Lynch’s investment principles? ↗

April 16, 2025

Peter Lynch’s approach focused on identifying undervalued growth stocks with simple, scalable businesses. We examine whether DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) fits the characteristics of a...

Via Chartmill

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗

April 09, 2025

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Via Benzinga

Topics Government Supply Chain World Trade

Would Peter Lynch consider DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) a winning stock? ↗

March 19, 2025

Let’s dive into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) using Peter Lynch’s key investing principles, from earnings growth and debt levels to long-term scalability and valuation.

Via Chartmill

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

March 18, 2025

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

March 18, 2025

From Alvotech

Via GlobeNewswire

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

March 13, 2025

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

February 06, 2025

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business ↗

January 23, 2025

Dr. Reddy's Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.

Via Benzinga

Dr. Reddy’s Q3 & 9MFY25 Financial Results

January 23, 2025

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Earnings Scheduled For January 23, 2025 ↗

January 23, 2025

Via Benzinga

CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices ↗

January 06, 2025

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions.

Via Benzinga

Topics Lawsuit

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio? ↗

December 22, 2024

The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio?

Via Benzinga

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

November 28, 2024

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

November 26, 2024

From Dr. Reddy's Laboratories, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.